Lurasidone: A new treatment option for schizophrenia

Drugs of Today

Volumn 47, Issue 11, 2011, Pages 807-816

  Owen, Richard T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DILTIAZEM; HALOPERIDOL; KETOCONAZOLE; LITHIUM; LURASIDONE; OLANZAPINE; QUETIAPINE; RIFAMPICIN; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; AMENORRHEA; ANXIETY DISORDER; ARTICLE; BACKACHE; BREAST AUGMENTATION; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERSALIVATION; INSOMNIA; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECEPTOR AFFINITY; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; ISOINDOLES; SCHIZOPHRENIA; THIAZOLES;

EID: 83255186320     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.11.1708832     Document Type: Article

References (32)

1. The Use of Medicines in the United States: Review of 2010. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/ Static%20File/IHII-UseOfMed-report.pdf. Accessed September 13, 2011.
2. Farah, A. Atypicality of atypical antipsychotics. J Clin Psychiatry 2005, 7(6): 268-74. (Pubitemid 44371604)
3. Leucht, S., Corves, C., Arbiter, D., Engel, R.R., Li, C., Davis, J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657): 31-41.
4. Leucht, S., Komossa, K., Rummel-Kluge, C. et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009, 166(2): 152-63.
5. Leucht, S., Kissling, W., Davis, J.M. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009, 39(10): 1591-2.
6. Ishibashi, T., Tokuda, K., Hotrizawa, T, Ogasa, M., Cuchiaro, J., Loebel, A. Receptor binding profile of lurasidone: a novel psychotropic agent under development for schizophrenia and bipolar disorder. Schizophr Bull 2009, 35(Suppl. 1): 139.
7. Ishibashi, T., Horisawa, T., Tokuda, K. et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5HT7) and 5HT1a receptor activity. J Pharmacol Exp Ther 2010, 334(1): 171-81.
8. Latuda (lurasidone) prescribing information http://www.latuda.com/ LatudaPrescribingInformation.pdf., Accessed September 13, 2011.
9. Meyer, J.M., Loebel, A.D., Schweizer, E. Lurasidone: a new drug in development for schizophrenia. Exp Opin Investig Drugs 2009, 18(11): 1715-26.
10. Food and Drug Administration. Drug approval package Latuda (lurasidone hydrochloride) tablets. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 200603Orig1s000TOC.cfm. Accessed September 13, 2011.
11. Harvey, P.D., Murasaki, M., Cuchiaro, J., Ogasa, M., Loebel, A. A three-arm dose-finding study of lurasidone: efficacy and tolerability data. Schizophr Res 2010, 117(2-3): 374-5.
12. Guarino, J., Loebel, A., Cucchiaro, J., Ogasa, M., Silva, R., Siu, C. Lurasidone for schizophrenia: symptomatic remission during short-term treatment. Schizophr Bull 2009, 36(Suppl. 1): 373.
13. Nakamura, M., Ogasa, M., Guarino, J. et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70(6): 829-36.
14. Lurasidone Meeting Slide Presentation http://www.dspharma.com/ir/library/ presentation/pdf/eir20090612.pdf Accessed September 13, 2011.
15. Meltzer, H.Y., Cucchiaro, J., Silva, R. et al. Lurasidone in the treatment of schizophrenia: a randomised, double-blind, placebo and olanzapine-controlled study. Am J Psychiatry 2011, 168(9): 957-67.
16. Study results: A comparison of study drug with placebo and haloperidol in patients with schizophrenia (NCT00044044). ClinicalTrials.gov Web site. Accessed September 13, 2011.
17. Latuda® (lurasidone HCl) significantly improves symptoms of schizophrenia in fifth positive placebo-controlled study [news release]. Sunovion Pharmaceuticals Inc. December 8, 2010. http://www.sunovion.com/news/ pressReleases/20101208.pdf. Accessed September 13, 2011.
18. Cucchiaro, J., Potkin, S.G., Ogasa, M., Loebel, A. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Bull 2009, 35(Suppl. 1): 342-3.
19. Harvey, P.D., Ogasa, M., Cucchiaro, J., Loebel, A, Keefe, R.S.E. Performance and interview-based assessments of cognitive change in a randomized double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 2011, 127(1-3): 188-94.
20. Citrome, L., Cucchiaro, J., Sarma, K. et al. Long-term safety and tolerability of lurasidone in schizophrenia or schizoaffective disorder: a 12-month, double-blind, active-controlled study. 164th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR06-09.
21. Hiroki, O., Masakumi, M., Masaaki, O., Cucchiaro, J., Siu, C., Loebel, A. A prospective, 1-year, open-label, flexible dose study of lurasidone in the treatment of schizophrenia: safety, tolerability and effectiveness. 164th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR06-22.
22. Loebel, A., Cucchiaro, J., Sarma, K. et al. Lurasidone in the treatment of of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week PEARL 3 trial. 164th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR06-38.
23. Loebel, A., Cucchiaro, J., Silva, R., Ogasa, M., Severs, J., Marder, S.R. Efficacy of lurasidone in schizophrenia: results of a pooled analysis based on a 5-factor model of schizophrenia. Schizophr Res 2010, 117(2-3): 267.
24. Harvey, P.D., Hsu, J., Cucchiaro, J., Pikalov, A., Siu, C., Maruff, P., Loebel, A. Cognitive performance in patients with acute schizophrenia treated with lurasidone: a double-blind, placebo-controlled trial. 164th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR06-20.
25. Silva, R., Cucchiaro, C., Hsu, J. et al. Effect of short-term treatment with lurasidone on quality of life in schizophrenia: results from the PEARL 3 trial. 164th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR06-57.
26. Potkin, S.G., Ogasa, M., Cucchiaro, J., Loebel, A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res 2011, 132(2-3): 101-7.
27. Completion of long-term phase 3 safety trial for Latuda (lurasidone HCl) [news release]. Dainippon Sumitomo Pharma, January 25, 2011. http://www.ds-pharma.com/pdf-view.php?id=62. Accessed September 13, 2011.
28. Stahl, S., Cucchiaro, J., Simonelli, D., Severs, J., Loebel, A. Long-term safety and tolerability of lurasidone in patients with schizophrenia: results of a 6-month open-label extension study. Schizophr Bull 2009, 35(Suppl. 1): 271.
29. Pikalov, A., Cucchiaro, J., Ogasa, M., Silva, R., Hsu, J., Loebel, A. Effect of lurasidone on weight and metabolic parameters: results from short-term placebo-controlled and long-term trials in schizophrenia. 164th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR06-49.
30. Tyrer, P., Kendall, T. The spurious advance of antipsychotic therapy. Lancet 2009, 373(9657): 4-5.
31. Oosterhuizen, P., Emsley, R., Maritz, J.S.M., Turner, J.A., Keyter, N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003, 64(9): 1075-80. (Pubitemid 37158253)
32. Clinical trials of lurasidone and bipolar depression. http://clinicaltrials.gov/ct2/results?term=lurasidone+and+bipolar. Accessed November 24, 2011.